Skip to content
Disclosery

Medicxi Ventures Management (Jersey) Ltd

Follow

13F filer, CIK 1715579, ST. HELIER, Jersey

Medicxi Ventures Management (Jersey) Ltd reported $427,250,674 across 5 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-07-08.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-25-006205

Period
2025-06-30
Reported value
$427M
Holdings
5
Top 10 weight
100%
New
1
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
RAPTnew+2,794,000$22.4M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
RAPT THERAPEUTICS INCexited-22,352,000-$27.3M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0000950123-25-006205, largest first. % of portfolio is the value over $427,250,674, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
CNTACENTESSA PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 19,963,157 shares; 2024Q4: 19,963,157 shares; 2025Q1: 19,963,157 shares; 2025Q2: 19,963,157 shares 19,963,157$262M61.4%0Timeline
PHATPHATHOM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 7,464,572 shares; 2024Q4: 7,464,572 shares; 2025Q1: 7,464,572 shares; 2025Q2: 7,464,572 shares 7,464,572$71.6M16.75%0Timeline
NAMSNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,869,565 shares; 2024Q4: 2,869,565 shares; 2025Q1: 2,869,565 shares; 2025Q2: 2,869,565 shares 2,869,565$52M12.16%0Timeline
RAPTRAPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 2,794,000 shares 2,794,000$22.4M5.23%newTimeline
AURAAURA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,039,892 shares; 2024Q4: 3,039,892 shares; 2025Q1: 3,039,892 shares; 2025Q2: 3,039,892 shares 3,039,892$19M4.45%0Timeline

Sold out in Q2 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INC22,352,000$27.3Mshares

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-25-006205 base2025-07-08acceptance time not in the bulk data set